Kanna Hayashi Selected Research

Therapeutics

1/2022	Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada.
1/2022	Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
1/2021	Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting.
1/2021	The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.
1/2020	Trajectories of retention in opioid agonist therapy in a Canadian setting.
1/2020	Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting.
1/2020	Temporal changes in non-fatal opioid overdose patterns among people who use drugs in a Canadian setting.
12/2019	Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
1/2019	Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
1/2019	Supervised Injection Facility Utilization Patterns: A Prospective Cohort Study in Vancouver, Canada.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kanna Hayashi Research Topics

Disease

20	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 07/2015
14	Substance-Related Disorders (Drug Abuse) 01/2022 - 01/2016
11	HIV Infections (HIV Infection) 12/2019 - 05/2011
10	HIV Seropositivity 12/2019 - 03/2014
9	Opiate Overdose 12/2021 - 01/2018
6	Drug Overdose 01/2022 - 01/2019
6	Hepatitis C 01/2019 - 09/2013
5	Pain (Aches) 01/2021 - 09/2015
4	Infections 01/2022 - 09/2017
4	Chronic Pain 01/2021 - 09/2015
2	Soft Tissue Infections 01/2019 - 09/2013
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2018 - 03/2016
2	Mental Disorders (Mental Disorder) 01/2018 - 09/2015
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	COVID-19 01/2022
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 05/2020
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020
1	Nausea 01/2020
1	Major Depressive Disorder (Major Depressive Disorders) 01/2018
1	Alcoholism (Alcohol Abuse) 01/2018
1	Marijuana Use 09/2015
1	Vascular System Injuries 05/2013

Drug/Important Bio-Agent (IBA)

24	Opioid Analgesics (Opioids)IBA 01/2022 - 09/2015
20	Pharmaceutical PreparationsIBA 01/2022 - 09/2013
16	Methadone (Dolophine)FDA LinkGeneric 11/2021 - 07/2015
10	Illicit Drugs (Recreational Drugs)IBA 01/2021 - 09/2015
9	Fentanyl (Sublimaze)FDA LinkGeneric 12/2021 - 01/2018
7	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 11/2021 - 09/2015
7	Heroin (Diamorphine)IBA 01/2021 - 09/2013
4	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2019 - 05/2011
3	Cocaine (Cocaine HCl)IBA 11/2019 - 11/2014
3	BenzodiazepinesIBA 05/2016 - 10/2015
2	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2017
1	Naloxone Drug Combination Buprenorphine FDA Link 01/2022
1	Hallucinogens (Psychedelics)IBA 01/2022
1	Therapeutic UsesIBA 01/2020
1	InterferonsIBA 01/2019
1	Reverse Transcriptase InhibitorsIBA 09/2017
1	tryptamineIBA 01/2017
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2017
1	Prescription DrugsIBA 10/2015
1	Analgesics (Analgesic Drugs)IBA 09/2015
1	Midazolam (Versed)FDA LinkGeneric 05/2013

Therapy/Procedure

19	Therapeutics 01/2022 - 01/2015
1	Dental Care 11/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Pain Management 01/2020
1	Aftercare (After-Treatment) 01/2020
1	Condoms (Condom) 12/2019
1	Injections 01/2019
1	Opiate Substitution Treatment 03/2016
1	Art Therapy 03/2016